P18071 OLD AML Post-Activity Assessment

Assessment Summary

0 of 21 questions completed

Questions:

You have already completed the assessment before. Hence you can not start it again.

Assessment is loading…

You must sign in or sign up to start the assessment.

You must first complete the following:

Results

Assessment complete. Results are being recorded.

Results

0 of 21 questions answered correctly

Your time:

You have reached 0 of 0 point(s), (0)

Answered
Review

Question 1 of 21

1. Question
1 point(s)
Why is the advent of risk (molecular) stratification in AML based on cytogenetics or karytype analysis, such an important scientific breakthrough?
- a. Favorable cytogenetics predict better long-term survival
- b. Treatment for the AML is completely dependent on the risk classifications established through molecular stratification
- c. There is a significant drop in overall survival with poor risk cytogenetics
- d. All of the above
Correct

Incorrect
Question 2 of 21

2. Question
1 point(s)
Which is not a significant characteristic of Acute Promyelocytic leukemia (APL)?
- a. It presents in younger patients
- b. It is associated with a high risk of bleeding
- c. Even if the patient survives the initial period of bleeding risk, he or she will have an extremely low cure rate.
- d. It is treated very differently from AML
Correct

Incorrect
Question 3 of 21

3. Question
1 point(s)
Which statement (below) is true regarding the targeted treatment of APL with ATRA:
- a. APL patients go to transplant within days of the beginning of treatment
- b. Treatment with ATRA stops the differentiation block in APL cells and leads to the differentiation of these blasts into normal cells
- c. Treatment of ATRA is not associated with differentiation syndrome
- d. Even in life threatening cases, treatment with ATRA is not interrupted
Correct

Incorrect
Question 4 of 21

4. Question
1 point(s)
The most commonly reported symptom associated with anemia is:
- a. Leg cramping
- b. Cough
- c. Fatigue
- d. Dry eye
Correct

Incorrect
Question 5 of 21

5. Question
1 point(s)
The nurse’s role in treating the side effects of neutropenia includes:
- a. Providing education related to signs and symptoms of infection
- b. Providing education related to signs and symptoms of bleeding
- c. Encouraging light exercise – i.e. walking
- d. All of the above
Correct

Incorrect
Question 6 of 21

6. Question
1 point(s)
The pharmacist plays a crucial role in supporting the treatment of AML patients by:
- a. Making antibiotic recommendations
- b. Monitoring therapeutic drugs
- c. Working with the patient’s physician to decide on the appropriate chemotherapy treatment
- d. All of the above
Correct

Incorrect
Question 7 of 21

7. Question
1 point(s)
In order to have a diagnosis of AML, patients must:
- a. Have more than 20% blasts or immature cells in their blood
- b. Have more than 10% blasts or immature cells in their blood
- c. Have a rapidly increasing white blood cell count
- d. Have a rapidly increasing red blood cell count
Correct

Incorrect
Question 8 of 21

8. Question
1 point(s)
Risk factors for AML include:
- a. Prolonged pneumonia
- b. Radiation exposure
- c. Previous chemotherapy
- d. b and c
Correct

Incorrect
Question 9 of 21

9. Question
1 point(s)
Elderly AML patients who are unfit:
- a. Do not go through the traditional 7 + 3 therapy
- b. Are given a low dose of agents and therefore may take several months to respond
- c. Do not experience a lot of organ toxicity while undergoing treatment
- d. All of the above
Correct

Incorrect
Question 10 of 21

10. Question
1 point(s)
Anthracyclines are an important part of the backbone of 7 + 3 therapy for AML. What common toxicities are seen with their use?
- a. Extravasation
- b. Myelosuppression
- c. Cardiotoxicity
- d. All of the above
Correct

Incorrect
Question 11 of 21

11. Question
1 point(s)
What are complications that AML patients may go through following stem cell transplant:
- a. Cardiotoxicity
- b. Fertility issues
- c. Meningitis
- d. a and b
Correct

Incorrect
Question 12 of 21

12. Question
1 point(s)
In a clinical trial for high risk AML patients who were 60 – 75 years old, the addition of Vyxeos™ (daunorubicin and cytarabine) to the standard 7 + 3 treatment, resulted in:
- a. A higher complete remission rate for patients who received the additional treatment
- b. Improved survival rate for patients who received the additional treatment
- c. Evidence to support FDA approval for Vyxeos™
- d. All of the above
Correct

Incorrect
Question 13 of 21

13. Question
1 point(s)
How is treatment for an AML patient who relapses 2 years (long-term) after remission different from treatment for a patient who relapses 6 months (short-term) after remission:
- a. Chemotherapy will not likely put either patient into remission
- b. Chemotherapy will most likely put the long-term patient into remission
- c. Chemotherapy will most likely put the short-term patient into remission
- d. The long-term remission patient should undergo a stem cell transplant
Correct

Incorrect
Question 14 of 21

14. Question
1 point(s)
In the clinical trial, RATIFY, the agent midostaurin was added to the standard 7 + 3 regimen for a randomized group of patients, 18 – 60 years of age. The control group was given the 7 + 3 regimen and a placebo. The patients who were given midostaurin:
- a. Had a better survival rate than the control group
- b. Had a worse survival rate than the control group
- c. Had a greater level of toxicity than the control group
- d. Could not undergo stem cell transplant after induction
Correct

Incorrect
Question 15 of 21

15. Question
1 point(s)
Following induction but before stem cell transplant, what are some important options that couples have in managing fertility:
- a. For men, sperm banking prior to transplant
- b. Refraining from sexual intimacy for at least 8 months prior to transplant
- c. For women, if their medical condition warrants, having surgery for oocyte preservation prior to transplant
- d. a and c
Correct

Incorrect
Question 16 of 21

16. Question
1 point(s)
Cytogenetic normal acute myeloid leukemia (AML) is:
- a. Associated with a poor prognosis
- b. Associated with a highly favorable prognosis
- c. A highly heterogeneous disease group
- d. A highly homogeneous disease group
Correct

Incorrect
Question 17 of 21

17. Question
1 point(s)
Which of the following are used to diagnosis AML?
- a. Bone marrow aspirate and biopsy morphologic evaluation
- b. Complete blood count
- c. Physical workup
- d. Swollen lymphnodes
Correct

Incorrect
Question 18 of 21

18. Question
1 point(s)
Goals of treatment in AML include inducing remission with a focus on improving quality of life for which of the following groups?
- a. Pediatrics
- b. Young adults
- c. Fit elderly
- d. Unfit elderly
Correct

Incorrect
Question 19 of 21

19. Question
1 point(s)
1. Which of the following is true regarding Hodgkin lymphoma?
- a. It is a solid tumor cancer
- b. It has a bimodal distribution, peaking at age of 20’s-30’s and then 60’s to 80’s
- c. More than 20,000 new cases are estimated to occur in the US annually
- d. Incidence peaks at age 40-50 years
Correct

Incorrect
Question 20 of 21

20. Question
1 point(s)
The most common toxicity in patients receiving ATRA (al trans retinoic acid) and arsenic trioxide is:
- a. Cardiac toxicity
- b. Dermatologic toxicity
- c. Hematologic toxicity
- d. Hepatic toxicity
Correct

Incorrect
Question 21 of 21

21. Question
1 point(s)
Why do younger AML patients have a higher rate of survival than older patients?
- a. Younger patients are better able to handle the toxicities associated with treatment
- b. Younger patients more readily go to stem cell transplants
- c. Older patients are more prone to certain genetic abnormalities
- d. a and b
Correct

Incorrect

P18071 OLD AML Post-Activity Assessment

Assessment Summary

Information

Results

Results

Categories

1. Question

2. Question

3. Question

4. Question

5. Question

6. Question

7. Question

8. Question

9. Question

10. Question

11. Question

12. Question

13. Question

14. Question

15. Question

16. Question

17. Question

18. Question

19. Question

20. Question

21. Question